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The corona virus disease 2019 (COVID-19) pandemic has resulted in the reorganization of 
healthcare settings affecting clinical care delivery to patients with Duchenne and Becker muscular 
dystrophy (DBMD) as well as other inherited muscular dystrophies. The magnitude of the impact 
of this public health emergency on the care of patients with DBMD is unclear as they are suspected 
of having an increased risk for severe manifestations of COVID-19. In this paper, the authors 
discuss their consensus recommendations pertaining to care of these patients during the pandemic. 
We address issues surrounding corticosteroid and exon skipping treatments, cardiac medications, 
hydroxychloroquine use, emergency/respiratory care, rehabilitation management, and the conduct 
of clinical trials. We highlight the importance of collaborative treatment decisions between the 
patient, family, and health care provider, considering any geographic or institution-specific 
policies and precautions for COVID-19. We advocate for continuing multidisciplinary care for 
these patients using telehealth.  
 




Corona virus disease 2019 (COVID-19) is a pandemic and public health emergency caused by the 
SARS-CoV-2 virus. COVID-19 symptoms include fever, cough, fatigue, shortness of breath, sore 
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throat, headache, diarrhea, and reduced smell and taste sensations. Severe manifestations including 
pneumonia, acute respiratory distress syndrome, cytokine storm, myocardial injury, and death are 
more common in older patients and those with medical co-morbidities1-5. The majority of children 
with COVID-19 in the United States who have required hospitalization had one or more underlying 
medical conditions such as chronic lung disease, cardiovascular disease, and immunosuppression6.  
Management is supportive, as there is no specific antiviral treatment currently available. Social 
distancing is crucial to limit the spread of COVID-196-8 which has necessitated a reorganization of 
healthcare settings and clinical practice9.  
 
Duchenne and Becker muscular dystrophies (DBMD) are x-linked recessive progressive muscle 
disorders caused by mutations in the dystrophin gene10. There is a concern that patients with 
DBMD may be at an increased risk of developing multi-systemic and severe complications of 
COVID-19 due to major comorbidities such as chronic immunosuppression from corticosteroids, 
respiratory insufficiency leading to poor airway clearance and the need for chronic ventilatory 
support, and cardiac dysfunction. Providing comprehensive multidisciplinary medical care, 
genetic testing for early diagnosis, proactive cardiac and respiratory care, and new therapeutic 
strategies including targeted treatments such as gene-based dystrophin restoration medications 
used in conjunction with corticosteroids, are reshaping the natural history of DBMD11-13. 
Currently, there are no data on how the COVID-19 public health emergency and resulting changes 
in health care delivery have impacted these patients. We assembled an expert panel of 
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neuromuscular specialists to provide recommendations related to the care of patients with DBMD 
and other muscular dystrophies during this public health emergency. Expert leaders in DBMD 
from across the USA were identified and invited to convene for the panel. The primary modes of 
communication were video/audio conferencing and email for a thorough point-by-point review to 
reach the consensus. This report, therefore, reflects the consensus opinion of the authors.   
 
Patients with DBMD and their families should follow current national, state, and local guidelines 
as well as any additional recommendations for people at risk for serious illness from COVID-1914, 
15. Patients and family members should vigilantly practice social distancing, including avoiding 
public gatherings and public transport, limiting time in stores, and using remote technology 
platforms in place of in-person meetings and activities, including the use of telehealth for medical 
care if clinically appropriate. 
 
DBMD patients should continue their current treatments, and specifically should not discontinue 
existing medications, unless approved by their treating neurologist or neuromuscular specialist. 
We recommend that patients continue their current corticosteroid treatment. However, should they 
become ill, they should notify their neurologist or neuromuscular specialist as their dose (amount 
or frequency) may need to be adjusted to prevent adrenal insufficiency. Stress dose corticosteroids 
should be considered in settings of acute sickness or hospitalization16. Patients and families should 
be aware of the risk of adrenal crisis during illness, or with sudden cessation of steroid use, and 
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discuss this with their health care providers. Appropriate dosing of stress dose corticosteroids has 
been published12, 16, 17. Consultation with an endocrinologist is recommended when steroid changes 
are being made during hospitalization. Vomiting is a rare symptom of COVID-19 but patients who 
cannot tolerate their regular doses of corticosteroids should seek medical attention for clinical 
assessment and parenteral steroid administration; alternatively, a family member should be 
prepared to deliver hydrocortisone intramuscularly.   
 
Exon skipping agents such as eteplirsen, golodirsen, and viltolarsen are antisense oligonucleotides 
that restore expression of a shorter but functional dystrophin. These are given as intravenous 
infusions over 35 to 60 minutes, once a week. Patients who are receiving these exon skipping 
agents are encouraged to continue the medications but should discuss with their neuromuscular 
specialist the risks versus benefits of continuing infusions during the pandemic. Home infusions 
should be considered as a potential measure to limit exposure to COVID-19. In the case of home 
infusions, or other home health care, it would be prudent to limit the number of visits to the 
necessary minimum, and ensure that providers wear appropriate personal protective equipment 
and are properly pre-screened for symptoms of COVID-19. 
 
Many patients with DBMD are prescribed angiotensin converting enzyme inhibitors or angiotensin 
receptor blockers for prophylaxis or treatment of cardiomyopathy. There has been some concern 
surrounding the use of these drugs due to the interplay of the SARS-CoV-2 virus and angiotensin 
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converting enzyme 2 which is a co-receptor for the virus. The American Heart Association, the 
American College of Cardiology, and the Heart Failure Society of America recently issued a joint 
statement that individuals should continue to take these medications in light of the known benefits 
to the heart and the uncertain risks of COVID-1918.   
 
We emphasize that treatment decisions should be individualized, and made jointly between the 
patient, family, and health care provider, considering any geographic or institution specific policies 
and precautions for COVID-19. Patients should not be labeled as “terminal” and triaged for non-
treatment simply on the basis of their disability and diagnosis. 
 
Comprehensive standard of care for patients with DBMD and other muscular dystrophies includes 
periodic assessments to monitor pulmonary, cardiac, and bone health as well as side effects from 
medications or treatments. These can include blood work, echocardiograms, cardiac MRIs, 
pulmonary function tests, x-rays, and dual energy x-ray absorptiometry for measuring bone 
mineral density11-13. Surging COVID-19 rates are placing a tremendous burden on healthcare 
systems, resulting in interruption of elective and/or non-emergent services and procedures. During 
this time, to enhance the safety of our patients, families, and medical staff, we recommend that 
standard practices be modified and individualized. Alternate options such as home blood draws, 
and home polysomnography if clinically appropriate, should be considered to minimize exposure 
and risk. In some cases, delaying routine laboratory monitoring can be appropriate, but if 
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management decisions necessitate acquisition of clinic-based laboratory studies such as pulmonary 
function tests, these can be safely performed with appropriate personal protective equipment. We 
encourage continuation of comprehensive care using telemedicine, single provider or multi-
disciplinary visits, for these patients.  
 
If patients with DBMD develop symptoms of COVID-19, their primary care physician and 
neuromuscular specialist should be notified. Concerning symptoms include a persistent fever over 
103 degrees Fahrenheit (39.4 degrees Celsius) that does not abate with antipyretics, a reduction in 
oxygen saturation, increased work of breathing, and decreased urinary output. Should symptoms 
warrant assessment in an emergency department, patients/families are advised to bring their home 
ventilatory support including ventilator, masks, and mechanical insufflation-exsufflation (cough 
assist) device with them and have their settings and respiratory treatment plans handy. To prevent 
spread of infection, ventilation systems should be changed to a full facemask or cuffed 
tracheostomy with closed tubing systems containing in-line filters19, 20.  Cough assist treatments 
should not be withheld due to concern for aerosolized particles. We advocate safely continuing 
frequent and scheduled cough assist treatments to enhance airway clearance with appropriate 
personal protective equipment for the caregivers or healthcare personnel providing the treatment. 
Patient/families should remind the treating healthcare providers that supplemental oxygenation 
without adequate ventilation in muscular dystrophy patients may exacerbate underlying chronic 
hypercapnia. Consultation with  pulmonology and/or anesthesiology specialists can be of great 
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value. If intubation is required, neuromuscular blockade should be avoided if possible and 
depolarizing agents such as succinylcholine are contraindicated. 
 
There has been widespread use of hydroxychloroquine for hospitalized COVID-19 patients.  The 
efficacy of hydroxychloroquine against COVID-19 is unclear with some small uncontrolled 
studies suggesting benefit, and at least one controlled study showing no benefit21.  There are 
potentially serious risks to skeletal and cardiac muscles.  Hydroxychloroquine causes a vacuolar 
myopathy in a minority of patients22, 23 and has also been associated with life threatening cardiac 
arrhythmias24.  Due to the uncertain benefits, and the potential risks to skeletal and cardiac muscle, 
hydroxychloroquine is not recommended for patients with DBMD. 
 
From a rehabilitation standpoint, the closures of schools and out-patient therapy facilities due to 
the COVID-19 pandemic has resulted in discontinuation of many therapy services. The clinical 
urgency of ongoing physical, occupational, and speech/language therapies should be evaluated on 
a case-by-case basis, and their suspension or continuation agreed upon by therapists, physicians, 
and patients. Tele-rehabilitation can be successfully implemented by therapy team members but 
the ability to perform varies based on local regulatory and compliance requirements. We encourage 
families and caregivers to use home therapy regimens recommended by their therapy team, if time 
allows, understanding the impact of added burdens and responsibilities experienced by caregivers. 
Additional rehabilitation considerations include using intermittent bracing, such as resting ankle-
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foot-orthoses/night splints or hand splints during planned daytime sedentary activities to help 
maintain passive range of motion; increasing physical activity and ambulation in the home and 
neighborhood to prevent worsening contractures and disuse weakness; and therapeutic positioning 
such as lying prone or standing with support to  provide a passive stretch to the hip flexors, knee 
flexors, and ankle plantar flexors4, 25, 26. Orthotists and equipment specialists may have limited 
availability during a pandemic which can limit necessary attention to bracing and equipment 
issues.   The therapy team and physicians can work together to prioritize issues and recommend 
in- person versus video appointments or telephone calls with orthotists or equipment specialists.  
Children with DBMD have a spectrum of neurobehavioral manifestations including intellectual 
disability, learning disabilities, anxiety, attention deficit hyperactivity, and autistic features27, 28. 
DBMD patients and their family members are at increased risk of depression and anxiety13. Mental 
health effects can be compounded during this pandemic due to multiple factors such as interrupted 
routines, school closures, anxiety and fear about the situation as well as limited availability or lack 
of mental health services. We highly recommend that psychological care and behavioral support 
continue via telehealth. 
Numerous clinical trials investigating targeted treatments for DMD are currently in progress.  The 
COVID-19 pandemic has impacted the conduct of clinical trials due to a variety of challenges such 
as quarantines, site closures, travel limitations, and interruptions in supply of investigational 
products29. These challenges affect adherence to protocol-specific procedures, protocol-mandated 
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visits and testing. Trial sponsors are actively pursuing alternate plans and telemedicine should be 
encouraged. Clinical trial sites have instituted policies pertaining to research conduct. We strongly 
recommend that considerations of participant and study staff safety remain the paramount concerns 
for any decisions regarding the need for in-person visits to the study site. Whenever possible, 
remote visits should replace in-person visits without compromising the collection of essential 
safety data.   Decisions around study visits should be made carefully after discussions involving 
patients, parents if applicable, investigator, study sponsor, and institutional review board. All 
discussions should be in keeping with institution-  and sponsor-specific policies, good clinical 
practice guidelines, and precautions for COVID-19 
 
Many of the management recommendations discussed above may also be relevant for patients with 
other muscular dystrophies such as some of the limb girdle and congenital muscular dystrophies.  
 
In conclusion, the COVID-19 pandemic presents tremendous challenges to the healthcare 
community, and disease-specific recommendations are rapidly evolving. We emphasize that for 
patients with DBMD: 
• Corticosteroids should be continued and stress dosing should be considered in the setting 
of illness and/or hospitalization. 
• Exon skipping medications can be continued after discussing the risks and benefits with 
the treating neuromuscular specialist. 
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• Angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers for 
prophylaxis or treatment of cardiomyopathy should  be continued. 
• Those with chronic respiratory insufficiency should be treated in collaboration with 
pulmonary and/or anesthesiology specialists and should not receive supplemental oxygen 
without ventilatory support. 
• Hydroxychloroquine should not be prescribed. 
• Standard of care assessments should be individualized and adjusted, balancing patient, 
caregiver and staff safety with the need for actionable information affecting important 
management decisions. 
We strongly recommend that healthcare providers practice strict adherence to established policies 
pertaining to the COVID-19 response and work closely with local and institutional authorities to 
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